Boston Scientific (NYSE: BSX) CEO sells stock after exercising options

Rhea-AI Filing Summary

Boston Scientific’s Chairman, President & CEO Michael F. Mahoney reported routine equity transactions in company stock. On February 2, 2026, he exercised stock options for 49,407 shares at $24.55 and 46,347 shares at $27.09, converting them into common stock.

That same day, he sold 1,200 shares at a weighted average price of $94.0567 and 159,701 shares at a weighted average price of $93.4905. The filing states these trades were made under a pre-established Rule 10b5‑1 trading plan adopted on August 29, 2025.

After these transactions, Mahoney directly owned 1,411,735 Boston Scientific common shares and had stock options for 231,739 and 98,814 shares from prior grants. He also indirectly held 213,679 shares through a trust.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mahoney Michael F

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MA 01752-1234

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman, President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		M(1)		49,407	A	$24.55	1,526,289	D
Common Stock	02/02/2026		M(1)		46,347	A	$27.09	1,572,636	D
Common Stock	02/02/2026		S(1)		1,200	D	$94.0567(2)	1,571,436	D
Common Stock	02/02/2026		S(1)		159,701	D	$93.4905(3)	1,411,735	D
Common Stock								213,679	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$27.09	02/02/2026		M(1)			46,347	(4)	02/15/2028	Common Stock	46,347	$0.0000	231,739	D
Stock Option (Right to Buy)	$24.55	02/02/2026		M(1)			49,407	(5)	02/28/2027	Common Stock	49,407	$0.0000	98,814	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 29, 2025.

2. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $94.00 to $94.13, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $93.00 to $93.985, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

4. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.

5. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.

	/s/ Susan Thompson, Attorney-in-Fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Boston Scientific (BSX) CEO Michael Mahoney report in this Form 4?

Michael F. Mahoney reported exercising stock options and selling Boston Scientific common shares. He converted options into 95,754 shares, then sold 160,901 shares in open-market transactions, all under a pre-established Rule 10b5-1 trading plan adopted on August 29, 2025.

How many Boston Scientific (BSX) stock options did the CEO exercise?

The CEO exercised two stock option grants covering 49,407 and 46,347 Boston Scientific shares. The options had exercise prices of $24.55 and $27.09 per share, respectively, turning those derivative positions into common stock before subsequent sales reported in the same Form 4.

How many Boston Scientific (BSX) shares did the CEO sell and at what prices?

He sold 1,200 Boston Scientific shares at a weighted average price of $94.0567 and 159,701 shares at a weighted average price of $93.4905. The filing notes these were executed in multiple trades within narrow price ranges on February 2, 2026.

Is the Boston Scientific (BSX) CEO’s stock sale part of a trading plan?

Yes. The Form 4 states the transactions were effected under a pre-established Rule 10b5-1 trading plan. That plan was adopted on August 29, 2025, allowing trades to be executed according to preset instructions rather than ad hoc decisions.

How many Boston Scientific (BSX) shares does the CEO own after these transactions?

After the reported trades, the CEO directly owned 1,411,735 Boston Scientific common shares. He also indirectly held 213,679 shares through a trust and retained stock options representing 231,739 and 98,814 underlying shares from prior option grants.

What are the remaining stock options held by the Boston Scientific (BSX) CEO?

Following the exercises, the CEO held 231,739 options from a grant expiring February 15, 2028, and 98,814 options from a grant expiring February 28, 2027. Both relate to prior awards that vest in four equal annual installments from their original grant dates.